Margaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.
Margaret von Mehren, MD, from the Fox Chase Cancer Center, discusses the rationale for evaluating ripretinib (DCC-2618) in patients with heavily pretreated advanced gastrointestinal stromal tumors (GIST) inthe phase III INVICTUS trial, which was presented at the European Society for Medical Oncology (ESMO) Congress 2019.
The tumors in patients with GIST are driven by mutations primarily in 2 genes, which includeKITand PDGFRα. There are 3 drugs currently approved by the FDA for the treatment of these patients, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), von Mehren says. Following treatment with these therapies, many patients are clinically well and healthy enough to proceed with more therapy. However, there is a lack of therapies available following the 3 FDA-approved drugs.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More